Financings

Achilles Therapeutics Ltd. closed a £100 million (US$120 million) series B round.

Gyroscope Therapeutics Ltd. raised £50.4 million (US$60.5 million).

Hifibio Therapeutics Inc. said it closed a $67 million series C financing round.

IGM Biosciences Inc. has filed to offer up to 7.81 million shares priced between $15 and $17 each in its IPO.

Nkarta Therapeutics Inc. completed an oversubscribed $114 million series B financing.

Passage Bio said it closed a $110 million series B financing led by Access Biotechnology with participation from existing investors.

Repare Therapeutics Inc. raised $82.5 million in a series B round.

Polypid Ltd. said it closed its $50 million series E-1 preferred shares financing round.

Spring Bank Pharmaceuticals Inc. said it entered a $20 million convertible debt financing agreement with Pontifax Medison Finance.

Springworks Therapeutics Inc. has filed to sell up to 7.35 million shares between $16 and $18 each in an IPO and applied to list its shares on Nasdaq under the symbol SWTX.

Viela Bio Inc. has filed to raise up to $150 million in an IPO.

Vir Biotechnology Inc. has filed to raise up to $100 million in an IPO.

Deals

Cidara Therapeutics Inc. is partnering with Mundipharma International Ltd. to develop and commercialize rezafungin for invasive fungal infections.

IMV Inc. and The Wistar Institute at the University of Pennsylvania have partnered to develop a targeted T-cell therapy to treat BRAF cancer mutations.

Sandoz AG, a division of Novartis AG, said it entered a global commercialization agreement with Polpharma Biologics SA for a proposed biosimilar of Tysabri (natalizumab, Biogen Inc.), for treating relapsing-remitting multiple sclerosis.

Valo Therapeutics Ltd. said it licensed from Helsinki University access to Peptienv technology that enables the coating of enveloped viruses by neoantigen-peptides. The technology is expected to improve the therapeutic response to enveloped oncolytic viruses in development for the treatment of cancer.

Vical Inc. said its stockholders voted to approve the proposals required to complete its merger with Brickell Biotech Inc.

Velabs Therapeutics GmbH entered an agreement with Alytas Therapeutics GmbH to develop modulatory and functional antibodies for an immune-based therapy against obesity.

Vertex Pharmaceuticals Inc. said it agreed to acquire privately held Semma Therapeutics Inc. for $950 million in cash.

Wntresearch AB and The Sage Group plc will collaborate to identify and engage potential partners before the phase II readout of Foxy-5, a synthetic hexapeptide with a formylated N-terminus, as neoadjuvant therapy in subjects with Wnt-5a low colon cancer.

Zyversa Therapeutics Inc. is collaborating with Selexis SA and KBI Biopharma Inc. to advance development of Zyversa's lead inflammasome inhibitor, IC-100, for the treatment of multiple inflammatory conditions.

... And more

AC Immune SA said The Michael J. Fox Foundation for Parkinson's Research has awarded a new grant for the company's alpha-synuclein positron emission tomography tracer program.

Aclaris Therapeutics Inc. said it will refocus resources on its immuno-inflammatory development programs and seek partners for its commercial products, following a strategic review of its business.

Delmar Pharmaceuticals Inc. has relocated its headquarters from Vancouver, British Columbia, to San Diego.

Eyegate Pharmaceuticals Inc. split its shares 1-for-15 and, as a result, is in compliance with minimum bid price requirements to maintain its Nasdaq listing.

Sutrovax Inc. received an award from CARB-X for up to $15 million in nondilutive funding to develop a universal vaccine to prevent infections caused by Group A Strep bacteria, which include pharyngitis, impetigo and necrotizing fasciitis.

Zafgen Inc. said it plans to explore strategic options to maximize shareholder value.

No Comments